Herseltpharma
ActiveSummary
Herseltpharma has been active since 2007 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €788k and a net result of €96k. Equity is growing by ~12.8% per year across the filed fiscal years. Its solvency ranks better than 65% of 9624 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.6% (low).
Checked score
Score 2024
Axes · tick = 2023
Profitability77▼-2
Solvency77▲+8
Growth78=
Track record100
Bankruptcy probability, 12 months
0.6%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €55k at 30 days acceptable
Liquidity tight (current ratio 1.31 against 0.89 in 2023; short-term debt: 34.7% and cash: 7.1% of total assets), and 48.4% of the assets are financed with debt.
Credit check for your own amount and term
Signals
Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
51.6%
Return on assets
6.3%
Age of the figures
21 mo
neutral · A punctual record breaks
This company filed 8 consecutive financial years on time. The year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 04-08-2025, 4 days late. Weigh it accordingly: a break into the 1-to-90-day band measures 1.41% abnormal legal state, below the 1.66% market average. It is a change in behaviour, not evidence of elevated risk.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
4 d late
2023
19 d early
2022
14 d early
2021
17 d early
2020
11 d early
2019
18 d early
← before the deadline
after the deadline →
Checked, nothing found (1)
Financials · fiscal year 2024, abbreviated schema
Equity
€788k▲ 13.9%
2023 · €692k
2018: €355klowest in 7 years
2019: €422k▲ +18.8% vs 2018
2020: €492k▲ +16.6% vs 2019
2021: €533k▲ +8.3% vs 2020
2022: €618k▲ +16.0% vs 2021
2023: €692k▲ +12.1% vs 2022
2024: €788k▲ +13.9% vs 2023highest in 7 years
2018 → 2024
Total assets
€1.53M▼ 2.8%
2023 · €1.57M
2018: €1.77Mhighest in 7 years
2019: €1.69M▼ -4.7% vs 2018
2020: €1.61M▼ -4.6% vs 2019
2021: €1.51M▼ -6.4% vs 2020
2022: €1.51M▼ -0.4% vs 2021lowest in 7 years
2023: €1.57M▲ +4.4% vs 2022
2024: €1.53M▼ -2.8% vs 2023
2018 → 2024
Net result
€96k▼ 26.3%
2023 · €130k
2018: €56k
2019: €67k▲ +20.0% vs 2018
2020: €70k▲ +4.7% vs 2019
2021: €41k▼ -41.7% vs 2020lowest in 7 years
2022: €85k▲ +108% vs 2021
2023: €130k▲ +53.2% vs 2022highest in 7 years
2024: €96k▼ -26.3% vs 2023
2018 → 2024
Working capital
€167k
2023 · €-65k
2018: €-254klowest in 7 years
2019: €-224k▲ +11.6% vs 2018
2020: €-194k▲ +13.5% vs 2019
2021: €-200k▼ -3.2% vs 2020
2022: €-114k▲ +43.1% vs 2021
2023: €-65k▲ +42.9% vs 2022
2024: €167k▲ +356% vs 2023highest in 7 years
2018 → 2024
Trend over the years
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20202021202220232024Trend
Equity€492k-€533k▲ 8.3%€618k▲ 16.0%€692k▲ 12.1%€788k▲ 13.9%
2020: €492klowest in 5 years
2021: €533k▲ +8.3% vs 2020
2022: €618k▲ +16.0% vs 2021
2023: €692k▲ +12.1% vs 2022
2024: €788k▲ +13.9% vs 2023highest in 5 years
Operating result€150k-€109k▼ 27.4%€168k▲ 54.1%€237k▲ 41.0%€210k▼ 11.2%
2020: €150k
2021: €109k▼ -27.4% vs 2020lowest in 5 years
2022: €168k▲ +54.1% vs 2021
2023: €237k▲ +41.0% vs 2022highest in 5 years
2024: €210k▼ -11.2% vs 2023
Net result€70k-€41k▼ 41.7%€85k▲ 108%€130k▲ 53.2%€96k▼ 26.3%
2020: €70k
2021: €41k▼ -41.7% vs 2020lowest in 5 years
2022: €85k▲ +108% vs 2021
2023: €130k▲ +53.2% vs 2022highest in 5 years
2024: €96k▼ -26.3% vs 2023
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result falls in 2024; 2024 is 11% below 2023.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €1.53M
Fixed assets
€830k ▼ 21.5%
Current assets
€697k ▲ 35.7%
Equity and liabilities €1.53M
Equity
€788k ▲ 13.9%
Debt
€740k ▼ 15.9%
Debt's share of the balance-sheet total falls from 56.0% to 48.4%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€356k▲
2023 · €326k
Cash flow
€241k▲
2023 · €220k
Current ratio
1.31▲
2023 · 0.89
Quick ratio
1.05▲
2023 · 0.65
Debt to equity
0.94▼
2023 · 1.27
ROE
12.2%▼
2023 · 18.8%
ROA
6.3%▼
2023 · 8.3%
Interest coverage
6.32▼
2023 · 6.53
Debt ≤ 1 year
€530k▼
2023 · €579k
Debt > 1 year
€194k▼
2023 · €291k
Income taxes
€59k▲
2023 · €57k
Staff costs
€206k▲
2023 · €180k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2024 against 2023 · 59 lines
Balance sheet
Code20232024
Assets
Total assets20/58€1.57M€1.53M▼
Fixed assets21/28€1.06M€830k▼
Intangible fixed assets21€256k€677k▲
Tangible fixed assets22/27€170k€153k▼
Land and buildings22€63k€56k▼
Plant, machinery and equipment23€22k€25k▲
Furniture and vehicles24€28k€19k▼
Other tangible fixed assets26€58k€53k▼
Financial fixed assets28€632k-
Current assets29/58€514k€697k▲
Stocks and contracts in progress3€138k€143k▲
Stocks30/36€138k€143k▲
Amounts receivable within one year40/41€137k€166k▲
Trade receivables40€136k€165k▲
Other amounts receivable41€1k€2k▲
Current investments50/53-€250k
Cash at bank and in hand54/58€205k€108k▼
Deferred charges and accrued income490/1€33k€30k▼
Equity and liabilities
Total equity and liabilities10/49€1.57M€1.53M▼
Equity10/15€692k€788k▲
Contributions10/11€64k€64k=
Reserves13€399k€495k▲
Non-distributable reserves130/1€6k€6k=
Reserves not available under the articles1311€6k€6k=
Distributable reserves133€393k€489k▲
Profit (loss) carried forward14€229k€229k=
Amounts payable17/49€880k€740k▼
Amounts payable after more than one year17€291k€194k▼
Financial debts170/4€291k€194k▼
Amounts payable within one year42/48€579k€530k▼
Current portion of amounts payable after more than one year42€96k€97k▲
Trade debts44€121k€124k▲
Suppliers440/4€121k€124k▲
Taxes, remuneration and social security45€51k€52k▲
Taxes450/3€34k€33k▼
Remuneration and social security454/9€17k€19k▲
Other amounts payable47/48€311k€258k▼
Accrued charges and deferred income492/3€10k€15k▲
Income statement
Code20232024
Remuneration, social security and pensions62€180k€206k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€89k€145k▲
Other operating charges640/8€608€2k▲
Gross operating margin9900€507k€563k▲
Operating profit (loss)9901€237k€210k▼
Financial income75/76B€110€1k▲
Recurring financial income75€110€1k▲
Financial charges65/66B€50k€56k▲
Recurring financial charges65€50k€56k▲
Profit (loss) for the period before taxes9903€187k€155k▼
Income taxes67/77€57k€59k▲
Profit (loss) for the period9904€130k€96k▼
Profit (loss) for the period to be appropriated9905€130k€96k▼
Appropriation of the result
Profit (loss) to be appropriated9906€360k€325k▼
Profit (loss) brought forward from the previous period14P€229k€229k=
Transfer from equity791/2€56k-
Transfer to equity691/2€130k€96k▼
To other reserves6921€130k€96k▼
Profit to be distributed694/7€56k-
Return on contributions (dividend)694€56k-
Social balance
Average headcount (FTE)90873.53.7▲
The notes to these accounts (15 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Accounts by statement
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | €484 | - | - | - | - |
| Remuneration, social security and pensions62 | - | €173k | €177k | €180k | €206k | ▲ 14.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €104k | €103k | €103k | €89k | €145k | ▲ 62.5% |
| Other operating charges640/8 | - | €585 | €805 | €608 | €2k | ▲ 200% |
| Non-recurring operating charges66A | - | €469 | - | - | - | - |
| Gross operating margin9900 | €403k | €386k | €449k | €507k | €563k | ▲ 11.1% |
| Operating profit (loss)9901 | €150k | €109k | €168k | €237k | €210k | ▼ 11.2% |
| Financial income75/76B | - | €17 | €75 | €110 | €1k | ▲ 874% |
| Recurring financial income75 | €16 | €17 | €75 | €110 | €1k | ▲ 874% |
| Financial charges65/66B | - | €51k | €47k | €50k | €56k | ▲ 12.5% |
| Recurring financial charges65 | €53k | €51k | €47k | €50k | €56k | ▲ 12.5% |
| Profit (loss) for the period before taxes9903 | €97k | €59k | €121k | €187k | €155k | ▼ 17.0% |
| Income taxes67/77 | €27k | €18k | €36k | €57k | €59k | ▲ 4.3% |
| Profit (loss) for the period9904 | €70k | €41k | €85k | €130k | €96k | ▼ 26.3% |
| Profit (loss) for the period to be appropriated9905 | €70k | €41k | €85k | €130k | €96k | ▼ 26.3% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €1.61M | €1.51M | €1.51M | €1.57M | €1.53M | ▼ 2.8% |
| Fixed assets21/28 | €1.29M | €1.19M | €1.14M | €1.06M | €830k | ▼ 21.5% |
| Intangible fixed assets21 | €448k | €384k | €320k | €256k | €677k | ▲ 164% |
| Tangible fixed assets22/27 | €207k | €177k | €185k | €170k | €153k | ▼ 10.0% |
| Land and buildings22 | - | €78k | €70k | €63k | €56k | ▼ 11.1% |
| Plant, machinery and equipment23 | - | €31k | €16k | €22k | €25k | ▲ 15.1% |
| Furniture and vehicles24 | - | - | €36k | €28k | €19k | ▼ 29.6% |
| Other tangible fixed assets26 | - | €68k | €63k | €58k | €53k | ▼ 8.8% |
| Financial fixed assets28 | €632k | €632k | €632k | €632k | - | - |
| Current assets29/58 | €327k | €319k | €369k | €514k | €697k | ▲ 35.7% |
| Stocks and contracts in progress3 | €108k | €111k | €121k | €138k | €143k | ▲ 3.2% |
| Stocks30/36 | - | €111k | €121k | €138k | €143k | ▲ 3.2% |
| Amounts receivable within one year40/41 | €106k | €109k | €127k | €137k | €166k | ▲ 21.3% |
| Trade receivables40 | - | €108k | €126k | €136k | €165k | ▲ 21.3% |
| Other amounts receivable41 | - | €1k | €1k | €1k | €2k | ▲ 19.8% |
| Current investments50/53 | - | - | - | - | €250k | - |
| Cash at bank and in hand54/58 | €95k | €76k | €93k | €205k | €108k | ▼ 47.5% |
| Deferred charges and accrued income490/1 | - | €22k | €28k | €33k | €30k | ▼ 8.2% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €1.61M | €1.51M | €1.51M | €1.57M | €1.53M | ▼ 2.8% |
| Equity10/15 | €492k | €533k | €618k | €692k | €788k | ▲ 13.9% |
| Contributions10/11 | - | €64k | €64k | €64k | €64k | = |
| Reserves13 | €199k | €240k | €325k | €399k | €495k | ▲ 24.0% |
| Non-distributable reserves130/1 | - | €6k | €6k | €6k | €6k | = |
| Reserves not available under the articles1311 | - | €6k | €6k | €6k | €6k | = |
| Distributable reserves133 | - | €233k | €318k | €393k | €489k | ▲ 24.4% |
| Profit (loss) carried forward14 | €229k | €229k | €229k | €229k | €229k | = |
| Amounts payable17/49 | €1.12M | €979k | €888k | €880k | €740k | ▼ 15.9% |
| Amounts payable after more than one year17 | €593k | €451k | €397k | €291k | €194k | ▼ 33.4% |
| Financial debts170/4 | - | €451k | €397k | €291k | €194k | ▼ 33.4% |
| Amounts payable within one year42/48 | €521k | €519k | €483k | €579k | €530k | ▼ 8.4% |
| Current portion of amounts payable after more than one year42 | - | €142k | €84k | €96k | €97k | ▲ 0.7% |
| Trade debts44 | €91k | €77k | €86k | €121k | €124k | ▲ 2.4% |
| Suppliers440/4 | - | €77k | €86k | €121k | €124k | ▲ 2.4% |
| Taxes, remuneration and social security45 | - | €39k | €52k | €51k | €52k | ▲ 2.3% |
| Taxes450/3 | - | €19k | €32k | €34k | €33k | ▼ 2.3% |
| Remuneration and social security454/9 | - | €20k | €21k | €17k | €19k | ▲ 11.4% |
| Other amounts payable47/48 | - | €261k | €260k | €311k | €258k | ▼ 17.2% |
| Accrued charges and deferred income492/3 | - | €9k | €8k | €10k | €15k | ▲ 56.5% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €70k | €41k | €85k | €130k | €96k | ▼ 26.3% |
| + Depreciation and write-downs630 | €104k | €103k | €103k | €89k | €145k | ▲ 62.5% |
| Operating cash flow (approximation) | €174k | €144k | €188k | €220k | €241k | ▲ 9.8% |
| Investment in fixed assets (approximation) | - | €-9k | €-47k | €-11k | €82k | ▲ 880% |
| Change in cash | - | €-19k | €17k | €112k | €-98k | ▼ 187% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
04-08
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema · 4 days late
2024
12-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
31-12
Financial
Highest result since 2018net €130k ▲53.2%
Operating result €237k, net result €130k, both a record.
17-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
14-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-12
Financial
Weakest financial yearnet €41k ▼41.7%
Net result drops to €41k, the lowest in the series; recovery starts the following year.
31-12
Financial
Equity above €500kEq €533k ▲8.3%
4 profitable years in a row build equity to €533k.
20-07
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
13-07
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
02-07
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
09-07
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema
2017
06-07
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema
2016
09-08
NBB filing
Annual accounts filed
fiscal year 2015 · abbreviated schema · 9 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 7 acts read
About the unread acts
We know of 7 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
7 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Herselt · 1 establishment unit since 2007
Ground area
1,493 m²
Building footprint
170 m²
Volume, LiDAR
1,376 m³
Parcel 13392M0310/00P000, Flanders · tallest building 9.7 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
Herseltpharma
since 20072.165.613.387
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 13392M0310/00P000 | Flanders | 1,493 m² | 1 · 170 m² | 9.7 m · 3 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Public money · subsidies and aid
Flemish government
2025 · 1 entry · 4,006 EUR awarded · 4,006 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 1 | 4,006 EUR | 4,006 EUR |
Schemes
Individueel Maatwerk
Recognitions · licences · registrations
Legal Entity Identifier
2549000P2S0AMJ6T2E34
Similar companies · same sector, comparable size
LAVISTA PHARMA
BE 0816.918.063
Courcelles · Eq €789,600
LINDEN
BE 0882.350.107
Beveren-Kruibeke-Zwijndrecht · Eq €789,692
Apotheek Heungens - Ghyzelings
BE 0881.542.334
Merelbeke-Melle · Eq €790,546
PHARMACIE DU RECIF
BE 0878.242.552
Elsene · Eq €790,667
LINDEPHAR
BE 0445.084.795
Evergem · Eq €791,171
Of 5,220 companies in sector 47730 we hold annual accounts for 3,861. 3,169 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded04-10-2007
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
64210Activities of holding companies
Scores and ratios are computed by Checked and are not a credit decision.